Skip to main content
. 2022 Oct 10;9(35):2202556. doi: 10.1002/advs.202202556

Figure 6.

Figure 6

mRNA‐derived hsACE2 protein neutralizes live SARS‐CoV‐2 and the pseudovirus with spike mutations in cells. a–c) Pseudovirus carrying a) the original spike protein (D614) of SARS‐CoV‐2, b) partial B.1.1.7 variant, or c) partial B.1.351 variant in 293T‐hACE2 cells. PBS (black), hsACE2 mRNA‐loaded lipofectamine 3000 (blue), and LNP‐Sito/hsACE2 (red). Pseudovirus were serially diluted for treatment, and normalized luciferase expression was measured (n = 3). Statistical analysis was performed using two‐way ANOVA with Sidak's multiple comparison tests. ****p < 0.0001; ***p < 0.001; **p < 0.01 compared to PBS‐treated group. d) Neutralization of SARS‐CoV‐2 infection by mRNA‐derived hsACE2 treatment in Vero E6 cells. Conditioned media derived from Fluc mRNA (black) or hsACE2 mRNA (blue) transfected 293T cells were treated to Vero E6 cells (n = 4). All data were expressed as the mean ± S.D. Statistical analysis was performed using two‐way ANOVA with Sidak's multiple comparison tests. ****p < 0.0001; ***p < 0.001; **p < 0.01 compared to Fluc mRNA‐treated group.